健保碼及健保價 
	See related Janumet[捷糖穩] information 
	 
	製造商 Merck Sharp & Dohme 
	代理/經銷商 Merck Sharp & Dohme 
	成份 Per 50/500 mg tab Sitagliptin 50 mg, metformin HCl 500 mg. Per 50/850 mg tab Sitagliptin 50 mg, metformin HCl 850 mg. Per 50/1000 mg tab Sitagliptin 50 mg, metformin HCl 1,000 mg
	適應症 As an adjunct to diet & exercise to improve glycemic control in patients with type 2 DM who are not adequately controlled on metformin or sitagliptin alone or in patient already being treated with the combination of sitagliptin & metformin.
	用量 Individualized dosage not exceeding max daily dose of sitagliptin 100 mg & metformin 2 g. Patients inadequately controlled with diet & exercise alone 50 mg/500 mg bid. Patients inadequately controlled on metformin monotherapy Sitagliptin 50 mg bid + metformin already taken. Patients inadequately controlled on sitagliptin monotherapy 50 mg/500 mg bid. May be titrated up to 50 mg/1000 mg bid. Switching from sitagliptin co-administered with metformin Initiate with dose of sitagliptin & metformin already being taken. Patients inadequately controlled on dual combination therapy with any 2 of the following antihyperglycemic agents: sitagliptin, metformin, sulfonylurea Sitagliptin 50 mg bid + metformin dose based on glycemic control level. Patients currently on or initiating sulfonylurea may require lower doses of sulfonylurea doses to reduce the risk of sulfonylurea-induced hypoglycemia. Gradual dose escalation to reduce GI effects associated with metformin.
	過量 View Janumet[捷糖穩] overdosage for action to be taken in the event of an overdose.
	用法 Should be taken with food
	美國食品藥物管理局之懷孕等級      
	     
	Category B: Either animal-reproduction studies have not demonstrated a foetal risk but there are no controlled studies in pregnant women or animal-reproduction studies have shown an adverse effect (other than a decrease in fertility) that was not confirmed in controlled studies in women in the 1st trimester (and there is no evidence of a risk in later trimesters). 
	禁忌 Renal disease or dysfunction, abnormal CrCl which may result from CV collapse, acute MI & septicemia. Acute or chronic metabolic acidosis including diabetic ketoacidosis, with or without coma. Temporarily discontinue treatment in patients undergoing radiologic studies. Type 1 diabetes, diabetic ketoacidosis.
	注意事項 Regular monitoring of renal function. Unstable or acute CHF at risk of hypoperfusion & hypoxemia. Lactic acidosis. Hypoglycemia. Avoid excessive alcohol intake. Suspend therapy prior to surgical procedure until resumption of oral intake & normal renal function. Impaired hepatic function. Monitor vit B12 level. Pregnancy & lactation. Children < 18 years. Elderly.
	不良反應 Diarrhea, nausea, vomiting, flatulence, abdominal discomfort, indigestion, asthenia & headache. Hypoglycemia. Hypersensitivity reactions.
	View ADR Monitoring Website[參閱藥物不良反應監測表格]
	交互作用 Metformin: Furosemide, nifedipine, cationic drugs (eg amiloride, digoxin, morphine, procainamide, quinidine, quinine, ranitidine, triamterene, trimethoprim, vancomycin). Thiazides & other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, OCs, phenytoin, nicotinic acid, sympathomimetics, Ca antagonists, INH.
	View more drug interactions with Janumet[捷糖穩]
	儲存 View Janumet[捷糖穩] storage conditions for details to ensure optimal shelf-life.
	描述 View Janumet[捷糖穩] description for details of the chemical structure and excipients (inactive components).
	作用 View Janumet[捷糖穩] mechanism of action for pharmacodynamics and pharmacokinetics details.
	本商品之市售規格
	劑型    包裝    圖片
	Janumet 50/500 mg 膜衣錠  Janumet 
	 
	Janumet 50/850 膜衣錠  Janumet 
	 
	Janumet 50/1000 膜衣錠  Janumet 
	 
	 
	Manufacturer: Merck Sharp & Dohme
	 
	Distributor: Merck Sharp & Dohme